

IC	Issue Date	Reference No.	Patent No.	Technology Title
CC	5/17/2011	E-046-2006	7,943,775	Small Molecules For Imaging Protein-protein Interactions In Alzheimer's Disease
	1/28/2014	E-147-2008	8,636,978	Tumor Targeted Thermally Sensitive Liposomes
	4/30/2019	E-149-2014	10,272,039	New Formulation Of Topical Sodium Nitrate Ointment
NCATS	9/23/2014	E-326-2008	8,841,305	Small Molecule Activators Of Human Pyruvate Kinase
	1/20/2015	E-326-2008	8,937,067	Small Molecule Activators Of Human Pyruvate Kinase
	8/11/2015	E-286-2011	9,101,600	Compounds As ROR γ Modulators And Uses Thereof
	11/3/2015	E-211-2010	9,173,898	Novel Compounds For Treatment Of Giardiasis
	3/22/2016	E-326-2008	9,290,512	Small Molecule Activators Of Human Pyruvate Kinase
	4/5/2016	E-074-2012	9,303,044	Small Molecule Inhibitors Of Alpha IIb Beta 3 Receptor For Potential Therapeutic Intervention Within Myocardial Infarction And Stroke
	5/31/2016	E-257-2010	9,353,117	Glucocerebrosidase Activators As A Treatment For Gaucher Disease
	6/14/2016	E-308-2009	9,365,612	Caspase 1 Inhibitor
	9/20/2016	E-240-2011	9,447,087	Human Galactokinase Inhibitors For The Treatment Of Galactosemia And Cancers
	9/27/2016	E-072-2012	9,452,973	Selective And Potent Modulators Of The Relaxin Receptor 1 (RXFP1)
	10/11/2016	E-144-2012	9,464,035	Non-inhibitory Chaperones Of Glucocerebrosidase
	5/30/2017	E-276-2011	9,663,521	PNC Modulators For The Treatment Of Metastasis And Tumorigenesis
	7/18/2017	E-120-2010	9,708,267	Substituted 3-oxo-3,4-dihydroquinoline-2H-benzo [b] [1,4] Oxazine-7-sulfonamides And 2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonamides Small Molecule Activators Of Human Pyruvate Kinase
	7/18/2017	E-326-2008	9,707,230	Small Molecule Activators Of Human Pyruvate Kinase
	8/15/2017	E-203-2012	9,730,941	METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1
	9/19/2017	E-287-2011	9,765,063	Amido Compounds As ROR γ Modulators And Uses Thereof
	10/31/2017	E-043-2013	9,802,904	Discovery Of Potent And Selective Inhibitors Of The USP1/UAF1 Deubiquitinase Complex
	5/22/2018	E-257-2010	9,974,789	Glucocerebrosidase Activators As A Treatment For Gaucher Disease
	11/13/2018	E-072-2012	10,125,112	Selective And Potent Modulators Of The Relaxin Receptor 1 (RXFP1)
	3/26/2019	E-040-2015	10,239,830	Compounds For Niemann Pick C And Other Lysosomal Storage Disorders
	4/23/2019	E-757-2013	10,266,488	4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS
	5/28/2019	E-276-2011	10,301,314	PNC Modulators For The Treatment Of Metastasis And Tumorigenesis
	9/17/2019	E-203-2012	10,413,548	METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1

IC	Issue Date	Reference No.	Patent No.	Technology Title
	11/12/2019	E-240-2011	10,471,061	Human Galactokinase Inhibitors For The Treatment Of Galactosemia And Cancers
	8/25/2020	E-757-2013	10,752,581	4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS
	2/16/2021	E-116-2016	10,919,842	CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE
	2/23/2021	E-257-2010	10,925,874	Glucocerebrosidase Activators As A Treatment For Gaucher Disease
NCI	3/9/2004	E-171-2000	6,703,046	Highly Cross-Linked, Extremely Hydrophobic Nitric Oxide-Releaseing Polymers And Methods For Their Manufacture And Use
	5/10/2005	E-050-2000	6,890,917	Geldanamycin Derivative And Method Of Treating Cancer Using Same
	8/30/2005	E-273-2002	6,936,639	NITROXYL PROGENITORS IN THE TREATMENT OF HEART FAILURE
	3/7/2006	E-249-2000	7,009,050	5-Substituted Derivatives of Conformationally locked Nucleoside Analogues
	4/17/2007	E-191-2002	7,205,334	CHONDROPSIN-CLASS ANTITUMOR V-ATPASE INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF.
	6/5/2007	E-171-2000	7,226,586	Highly Cross-Linked, Extremely Hydrophobic Nitric Oxide-Releaseing Polymers And Methods For Their Manufacture And Use
	11/27/2007	E-170-2004	7,300,940	Second Generation Integrin Avb3 Antagonists For Use In Imaging And Therapy
	12/25/2007	E-253-2003	7,312,228	Cytotoxic Indeno- And Isoindenoisoquinoline Compounds
	4/15/2008	E-030-2004	7,358,377	Novel Schweinfurthin Analogs As Anticancer Agents
	1/13/2009	E-087-2004	7,476,692	Novel And Stable Pharmaceutical Formulations Of L-threo-dihydrosphingosine ("Safingol")
	2/24/2009	E-112-2006	7,495,100	Synthesis Of Indenoisoquinolines
	4/21/2009	E-191-2002	7,521,475	CHONDROPSIN-CLASS ANTITUMOR V-ATPASE INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF.
	8/11/2009	E-276-2005	7,574,340	Novel Small Molecule Inhibitors Of Botulinum Neurotoxin Metalloprotease Activity
	10/27/2009	E-065-2005	7,608,594	Identification Of Novel Derivatives Of Novobiocin That Have A Higher Affinity For Binding To Hsp90 Than The Parent Compound And Therefore Are More Potent As Hsp90 Inhibitors
	11/24/2009	E-065-2005	7,622,451	NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS

IC	Issue Date	Reference No.	Patent No.	Technology Title
	2/2/2010	E-195-2001	7,655,694	Phytoestrogenic Isoflavone Compositions, Their Preparation, And Use Thereof For Protection Against Treatment of Radiation Injury
	10/5/2010	E-103-2002	7,807,472	p-Toluenesulfonhydrazide Derivatization for Separation and Measurement of Endogenous Estrogen Metabolites by High-Performance Liquid...
	10/12/2010	E-065-2005	7,811,998	Identification Of Novel Derivatives Of Novobiocin That Have A Higher Affinity For Binding To Hsp90 Than The Parent Compound And Therefore Are More Potent As Hsp90 Inhibitors
	1/4/2011	E-273-2002	7,863,262	NITROXYL PROGENITORS IN THE TREATMENT OF HEART FAILURE
	3/8/2011	E-030-2004	7,902,228	Novel Schweinfurthin Analogs As Anticancer Agents
	4/19/2011	E-279-2005	7,928,079	Poly-saccharide-derived Nitric Oxide-releasing Carbon-bound Diazeniumdiolates
	6/14/2011	E-065-2005	7,960,353	NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS
	6/21/2011	E-261-2005	7,964,365	Method For Diagnosing And Monitoring The Progression Of Cancer By Measuring CMet Ectodomain Shed In Bodily Fluids
	11/8/2011	E-029-2006	8,053,443	Novel Indenoisoquinoline Derivatives As Anti-proliferative Agents In Cancer Treatment
	3/27/2012	E-080-2006	8,143,252	A New Series Of Thalidomide Analogs That Have Potent Anti-angiogenic Properties
	5/29/2012	E-200-2007	8,188,055	Folate Ester Derivatives Of O6-Benzyl-2'-deoxyguanosine And O6-[4-(hydroxymethyl)benzyl]guanine
	7/3/2012	E-065-2005	8,212,011	Novobiocin Analogues
	7/3/2012	E-065-2005	8,212,012	Novobiocin Analogues Having Modified Sugar Moieties
	8/14/2012	E-070-2005	8,242,160	Small Molecular Inhibitor Of Ubiquitin Activating Enzyme (E1)
	9/18/2012	E-175-2002	8,268,890	METHOD OF TREATING ISCHEMIA/REPERFUSION INJURY WITH NITROXYL ANION DONORS
	10/2/2012	E-191-2002	8,278,348	CHONDROPSIN-CLASS ANTITUMOR V-ATPASE INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF.
	10/2/2012	E-247-2008	8,278,100	Use Of Lasonolide A To Induce Premature Chromosome Condensation And As A Novel Anti-cancer Agent
	10/16/2012	E-226-2006	8,288,530	Synthesis And Use Of Two Protected Variants Of The 1B4M DTPA
	11/6/2012	E-086-2007	8,303,960	Radiolabeling Of Affibody Molecules With F-18

IC	Issue Date	Reference No.	Patent No.	Technology Title
	11/6/2012	E-261-2005	8,304,199	Method For Diagnosing And Monitoring The Progression Of Cancer By Measuring CMet Ectodomain Shed In Bodily Fluids
	1/8/2013	E-195-2001	8,349,888	Phytoestrogenic Isoflavone Compositions, Their Preparation, And Use Thereof For Protection Against Treatment of Radiation Injury
	4/2/2013	E-064-2008	8,410,292	Epoxy-guaiane Selective Renal Cancer Inhibitors
	6/25/2013	E-315-2007	8,470,888	Novel Natural Product Inhibitors Of ABCG2
	11/12/2013	E-316-2008	8,579,787	Methods And Systems For Confining Drugs To A Region Of The Body
	12/17/2013	E-191-2002	8,609,716	CHONDROPSIN-CLASS ANTITUMOR V-ATPASE INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF.
	12/31/2013	E-261-2005	8,617,831	Method For Diagnosing And Monitoring The Progression Of Cancer By Measuring CMet Ectodomain Shed In Bodily Fluids
	1/21/2014	E-019-2010	8,633,177	Novel Nitroxyl (HNO) Prodrugs And Biomedical Applications Thereof
	3/18/2014	E-199-2002	8,673,888	Use of Depsipeptide in the Treatment of Renal Cell Carcinoma
	4/1/2014	E-073-2014	8,686,146	7-Azaindenoisoquinoline Topoisomerase I Inhibitors
	4/1/2014	E-183-2009	8,686,016	The Natural Product Schweinfurthin A And Synthetic Schweinfurthin Analogs Specifically Inhibit NF1-null Cells And May Be Useful As A Therapy For Neurofibromatosis Type 1.
	5/6/2014	E-199-2010	8,716,295	Fluoroquinolone Derivatives As Inhibitors Of Human Tyrosyl-DNA Phosphodiesterase (Tdp1)
	5/20/2014	E-295-2008	8,729,053	Novel Inhibitor Of NFkB
	9/9/2014	E-029-2006	8,829,022	Novel Indenoisoquinoline Derivatives As Anti-proliferative Agents In Cancer Treatment
	10/7/2014	E-133-2009	8,853,277	Use Of Tempol For Treatment Of Cancer
	10/21/2014	E-097-2006	8,865,686	Tetracyclines And Derivatives As Inhibitors Of Human Tyrosyl-DNA-phosphodiesterase (Tdp1)
	11/4/2014	E-138-2006	8,877,765	A Water Soluble Small Molecule Inhibitor Of P53 Degradation: Pyrimido[4,5]quinoline-2,4(3H,10H)-dione,5-[[3-(dimethylamino)propyl]amino]3,10-dimethyl-,monohydrochloride (NCS # 373989)
	12/16/2014	E-211-2005	8,912,214	Inhibitors Of The Protein Kinase Chk2 To Abrogate Apoptosis And Sensitize Cancer Cells To DNA Targeted Therapies
	2/17/2015	E-287-2007	8,957,027	Deacetylase Inhibitor Therapy
	3/31/2015	E-081-2011	8,993,768	Hydroxytropolone Inhibitors Of HIV-1 And XMRV Ribonuclease H

IC	Issue Date	Reference No.	Patent No.	Technology Title
	4/21/2015	E-131-2011	9,012,647	The Development Of Antioxidant NSAID For Chronic Treatment Of Diseases Related To Inflammation
	5/19/2015	E-073-2014	9,034,870	7-Azaindenoisoquinoline Topoisomerase I Inhibitors
	8/18/2015	E-316-2008	9,108,035	Methods And Systems For Confining Drugs To A Region Of The Body
	9/1/2015	E-065-2005	9,120,774	NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES
	10/27/2015	E-220-2011	9,168,266	PARP-inhibitor/NO-donor Dual Prodrugs As Anticancer Agents
	12/8/2015	E-025-2010	9,205,091	Nitric Oxide-based Cancer Therapeutic Agents For Lung Cancers With Elevated Levels Of Reactive Oxygen Species (ROS) And/or Low Levels Of Antioxidant Defense/DNA Repair Mechanisms.
	12/22/2015	E-029-2006	9,217,010	Novel Indenoisoquinoline Derivatives As Anti-proliferative Agents In Cancer Treatment
	1/19/2016	E-050-2010	9,238,069	Use Of Cucurbitacins And Withanolides To Sensitize Cancer Cells To The Cytotoxic Effects Of Apo2L/TRAIL
	4/19/2016	E-315-2007	9,314,448	Novel Natural Product Inhibitors Of ABCG2
	5/3/2016	E-082-2014	9,328,073	ALCOHOL-, DIOL-, AND CARBOHYDRATE-SUBSTITUTED INDENOISOQUINOLINES AS TOPOISOMERASE I INHIBITORS
	7/12/2016	E-029-2006	9,388,211	Novel Indenoisoquinoline Derivatives As Anti-proliferative Agents In Cancer Treatment
	7/26/2016	E-029-2006	9,399,660	Novel Indenoisoquinoline Derivatives As Anti-proliferative Agents In Cancer Treatment
	1/10/2017	E-157-2012	9,540,471	Polyvinylpyrrolidone (povidone) Derivatives Capable Of Serving As Nitric Oxide Donors
	1/10/2017	E-508-2013	9,540,415	Method For Inhibiting The Intestinal Farnesoid X Receptor To Decreases Obesity-Associated Non-Alcoholic Fatty Liver Disease (NAFLD)
	6/13/2017	E-090-2014	9,676,788	Aza-englerin Analogues And Use In Cancer Therapy
	6/13/2017	E-093-2013	9,676,771	Substituted 4-amino-N-(2,4-difluorobenzyl)-1-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamides With Improved Efficacy Against Viral Constructs Harboring Mutant Strains Of HIV-1 Integrase
	4/10/2018	E-316-2007	9,937,217	Novel Natural Product Inhibitors Of ABCG2 From The Developmental Therapeutics Program Compound Collection
	9/11/2018	E-015-2011	10,071,945	A New Chemical Class Of Antiandrogen For The Treatment Of Castrate-resistant Prostate Cancer

IC	Issue Date	Reference No.	Patent No.	Technology Title
	10/2/2018	E-292-2014	10,086,108	A Multiple Phase Transitioning Peptide Hydrogel For Use In Vascular Anastomosis
	11/20/2018	E-116-2014	10,131,659	Development Of Analogs Of Diphenylene Iodonium And Di-thienyl-iodonium As Inhibitors Of NADPH Oxidases And Other Flavin Dehydrogenases For The Treatment And Prevention Of Cancer And Inflammation-related Conditions
	11/27/2018	E-111-2013	10,137,212	Hydroxamate-based Chelators For The Complexation Of Zr-89 For Nuclear Imaging Of Cancers
	2/19/2019	E-093-2013	10,208,035	Substituted 4-amino-N-(2,4-difluorobenzyl)-1-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamides With Improved Efficacy Against Viral Constructs Harboring Mutant Strains Of HIV-1 Integrase
	3/19/2019	E-508-2013	10,233,209	Method For Inhibiting The Intestinal Farnesoid X Receptor To Decreases Obesity-Associated Non-Alcoholic Fatty Liver Disease (NAFLD)
	5/7/2019	E-271-2014	10,280,307	A New Class Of Stable Heptamethine Cyanine Fluorophores And Biomedical Applications Thereof
	5/14/2019	E-072-2014	10,287,297	Renal Selective Unsaturated Englerin Analogues
	11/5/2019	E-019-2014	10,464,970	A Class Of Compounds That Bind To The HIV-1 Rev Response Element Much Tighter Than The Rev
	11/5/2019	E-266-2015	10,464,881	Process For Preparing Z-endoxifen Of High Purity
	11/26/2019	E-176-2015	10,487,365	COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF CERVICAL CANCER AND CERVICAL INTRAEPITHELIAL NEOPLASIA
	2/11/2020	E-080-2014	10,556,916	Generation And Use Of Zr-89 Oxine Complex, A Long-lasting Cell Labeling Agent For Positron EmissionTomography (PET) Imaging
	2/18/2020	E-245-2016	10,561,729	Improved Near-IR Light Antibody Drug Conjugates (ADCs)
	8/4/2020	E-208-2015	10,730,835	Thalidomide/lenolidomide/pomalidomide Analogs That Inhibit Inflammation, Angiogenesis
	8/11/2020	E-015-2011	10,737,995	A New Chemical Class Of Antiandrogen For The Treatment Of Castrate-resistant Prostate Cancer
	8/11/2020	E-116-2014	10,738,047	Development Of Analogs Of Diphenylene Iodonium And Di-thienyl-iodonium As Inhibitors Of NADPH Oxidases And Other Flavin Dehydrogenases For The Treatment And Prevention Of Cancer And Inflammation-related Conditions

IC	Issue Date	Reference No.	Patent No.	Technology Title
	11/17/2020	E-208-2015	10,836,721	Thalidomide/lenolidomide/pomalidomide Analogs That Inhibit Inflammation, Angiogenesis
	12/1/2020	E-051-2016	10,850	Specific 17-beta-hydroxywithanolides Sensitize Cancer Cells To Apoptosis In Response To Toll-like Receptor (TLR) Ligands
	12/29/2020	E-245-2016	10,874,739	Improved Near-IR Light Antibody Drug Conjugates (ADCs)
	12/29/2020	E-271-2014	10,876,003	A New Class Of Stable Heptamethine Cyanine Fluorophores And Biomedical Applications Thereof
	2/2/2021	E-275-2014	10,906,914	Furoquinolinedione Derivatives As Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Inhibitors
	2/9/2021	E-035-2017	10,913,709	A Formulation Of GLG-302 Providing Improved Handling And Oral Bioavailability
	3/30/2021	E-046-2019	10,961,193	Non-aggregating Heptamethine Cyanine Fluorophores For In Vivo Imaging
NHGRI	11/23/2010	E-055-2005	7,838,531	Methods And Use Of Farnesyl Transferase Inhibitors (FTIs) For Laminopathies, Cellular Aging, And Artherosclerosis
	4/2/2013	E-217-2007	8,410,063	Provision Of The Neutral Sugar N-acetyl Nammosamine (ManNAc) For Increased Intracellular Production Of Sialic Acids
	9/9/2014	E-055-2005	8,828,356	Methods And Use Of Farnesyl Transferase Inhibitors (FTIs) For Laminopathies, Cellular Aging, And Artherosclerosis
	8/4/2015	E-217-2007	9,095,597	Provision Of The Neutral Sugar N-acetyl Nammosamine (ManNAc) For Increased Intracellular Production Of Sialic Acids
	9/20/2016	E-060-2011	9,446,048	Novel Compounds For A New Targeted Therapy To Treat Leukemia
	7/2/2019	E-217-2007	10,335,426	Provision Of The Neutral Sugar N-acetyl Nammosamine (ManNAc) For Increased Intracellular Production Of Sialic Acids
	3/23/2021	E-217-2007	10,953,026	Provision Of The Neutral Sugar N-acetyl Nammosamine (ManNAc) For Increased Intracellular Production Of Sialic Acids
NHLBI	12/27/2011	E-167-2008	8,085,041	A Three Point Method For Fast And Robust Magnetic Field Mapping
	8/27/2013	E-291-2009	8,518,968	A Class Hydrazone And Diacyl Hydrazine ERAD Inhibitors Are Highly Active Against Hematologic Tumor Cells Including Cells Resistant To The Proteasome Inhibitor Bortezomib
	10/1/2013	E-253-2009	8,547,533	Labels For Superresolution Microscopy Using The STAQ Concept (Superresolution Via Transiently Activated Quenchers)

IC	Issue Date	Reference No.	Patent No.	Technology Title
	1/28/2014	E-208-2007	8,637,560	Eeyarestatin Is A Deubiquination Inhibitor That Is Highly Active Against Hematologic Tumor Cells Including Cells Resistant To The Proteasome Inhibitor Bortezomib
	1/6/2015	E-254-2003	8,927,030	Treatment Of Specific Cardiovascular Conditions Using Nitrite Therapy
	3/1/2016	E-253-2009	9,273,089	Labels For Superresolution Microscopy Using The STAQ Concept (Superresolution Via Transiently Activated Quenchers)
	7/12/2016	E-254-2003	9,387,224	Treatment Of Specific Cardiovascular Conditions Using Nitrite Therapy
	6/13/2017	E-254-2003	9,675,637	Treatment Of Specific Cardiovascular Conditions Using Nitrite Therapy
	7/11/2017	E-254-2003	9,700,578	Treatment Of Specific Cardiovascular Conditions Using Nitrite Therapy
NIA	12/26/2006	E-141-2000	7,153,882	Agents Useful For Reducing Amyloid Precursor Protein And Treating Dementia And Methods of Use Thereof
	8/31/2010	E-141-2000	7,786,162	Agents Useful For Reducing Amyloid Precursor Protein And Treating Dementia And Methods of Use Thereof
	7/5/2011	E-189-2003	7,973,057	Thiothalidomides: Novel Isoteric Analogues Of Thalidomide With Enhanced TNF-a Inhibitory Activity
	9/4/2012	E-141-2000	8,258,172	Agents Useful For Reducing Amyloid Precursor Protein And Treating Dementia And Methods of Use Thereof
	4/22/2014	E-205-2006	8,703,826	Preparation Of R,R-fenoterol And R,R-fenoterol Analogues And Their Use In Congestive Heart Failure
	1/6/2015	E-045-2012	8,927,725	THIO ANALOGS OF LENALIDOMIDE
	7/21/2015	E-045-2012	9,084,783	THIO ANALOGS OF LENALIDOMIDE
	11/15/2016	E-013-2010	9,492,405	THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS
	12/20/2016	E-205-2006	9,522,871	Preparation Of R,R-fenoterol And R,R-fenoterol Analogues And Their Use In Congestive Heart Failure
	4/18/2017	E-045-2012	9,623,020	THIO ANALOGS OF LENALIDOMIDE
	5/16/2017	E-092-2011	9,650,352	The Use Of (2S,6S)-hydroxynorketamine And Other Hydroxylated Metabolites Of (R,S)-ketamine In The Treatment Of Depression
	1/16/2018	E-092-2011	9,867,830	The Use Of (2S,6S)-hydroxynorketamine And Other Hydroxylated Metabolites Of (R,S)-ketamine In The Treatment Of Depression
	3/6/2018	E-205-2006	9,908,841	Preparation Of R,R-fenoterol And R,R-fenoterol Analogues And Their Use In Congestive Heart Failure

IC	Issue Date	Reference No.	Patent No.	Technology Title
	11/20/2018	E-013-2010	10,130,594	THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS
	11/20/2018	E-139-2012	10,130,593	(R,R')-4'-methoxy-1-naphthylfenoterol (MNF) For The Treatment Of Glioblastomas And Hepatocellular Carcinomas
	3/5/2019	E-045-2012	10,220,028	THIO ANALOGS OF LENALIDOMIDE
	6/4/2019	E-205-2006	10,308,591	Preparation Of R,R-fenoterol And R,R-fenoterol Analogues And Their Use In Congestive Heart Failure
	11/26/2019	E-139-2012	10,485,771	(R,R')-4'-methoxy-1-naphthylfenoterol (MNF) For The Treatment Of Glioblastomas And Hepatocellular Carcinomas
	2/18/2020	E-205-2006	10,562,843	Preparation Of R,R-fenoterol And R,R-fenoterol Analogues And Their Use In Congestive Heart Failure
	4/14/2020	E-013-2010	10,617,654	THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS
	9/15/2020	E-139-2012	10,772,849	(R,R')-4'-methoxy-1-naphthylfenoterol (MNF) For The Treatment Of Glioblastomas And Hepatocellular Carcinomas
	2/23/2021	E-013-2010	10,925,840	THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS
NIAAA	2/4/2014	E-060-2010	8,642,654	Hydroxybutyrate Ester And Medical Use Thereof
	5/19/2015	E-061-2010	9,034,613	Enantioselective Synthesis Of A Hydroxybutyrate Ester
	2/28/2017	E-258-2012	9,579,302	Ketone Bodies To Protect Tissues From Damage By Ionizing Radiation
	9/19/2017	E-282-2012	9,765,031	Novel Peripherally Restricted CB1 Receptor Inverse Agonists For The Treatment Of Diabetes And Obesity
	6/25/2019	E-140-2014	10,329,259	Peripherally Restricted 4,5-Dihydro-1H-Pyrazole Derivatives
	1/14/2020	E-210-2012	10,531,803	Intralipid As A Contrast Agent To Enhance Subsurface Blood Flow Imaging
	6/16/2020	E-282-2012	10,683,270	Novel Peripherally Restricted CB1 Receptor Inverse Agonists For The Treatment Of Diabetes And Obesity
	9/29/2020	E-282-2012	10,787,419	Novel Peripherally Restricted CB1 Receptor Inverse Agonists For The Treatment Of Diabetes And Obesity
NIAID	10/4/2005	E-031-2004	6,951,961	Methods Of Use And Compositions For The Diagnosis And Treatment Of Infectious Disease
	12/4/2007	E-049-2004	7,303,751	Anti-Plasmodium Compositions And Methods Of Use
	11/30/2010	E-031-2004	7,842,729	Anti-Tubercular Drug: Compositions And Methods
	12/20/2011	E-051-2002	8,080,554	Method of Controlling Inflammation

IC	Issue Date	Reference No.	Patent No.	Technology Title
	7/10/2012	E-109-2007	8,216,788	Highly Sensitive Detection Of Infectious Prion Protein By Seeded Conversion Of Recombinant Prion Protein
	9/18/2012	E-031-2004	8,268,894	Anti-Tubercular Drug: Compositions And Methods
	6/4/2013	E-270-2004	8,455,437	Oxygenation Inhibits The Phsiological Tissue-protecting Mechanism And Thereby Exacerbates Acute Inflammatory Lung Injury
	12/31/2013	E-202-2008	8,618,090	Plasmodial Surface Anion Channel Antagonists As Lead Molecules For Antimalarial Drug Development
	5/6/2014	E-051-2002	8,716,301	Method of Controlling Inflammation
	10/28/2014	E-184-2010	8,871,789	Use Of Dimethylloxalylglycine (N-methoxyoxoacetyl-glycine Methyl Ester, "DMOG") And Analogs As Inhibitors For Depletion Of The JMJD Family Of Enzymes To Prevent Herpes Simplex Virus Infections And Reactivation From Latency
	4/12/2016	E-238-2012	9,309,237	HIV Inhibitors
	4/26/2016	E-145-2011	9,320,786	The Plasmodial Surface Anion Channel As A Target For Antimalarial Therapy
	7/19/2016	E-202-2008	9,394,316	Plasmodial Surface Anion Channel Antagonists As Lead Molecules For Antimalarial Drug Development
	8/16/2016	E-051-2002	9,415,105	Method of Controlling Inflammation
	11/7/2017	E-145-2011	9,808,458	The Plasmodial Surface Anion Channel As A Target For Antimalarial Therapy
	5/22/2018	E-202-2008	9,974,796	Plasmodial Surface Anion Channel Antagonists As Lead Molecules For Antimalarial Drug Development
	4/23/2019	E-145-2011	10,265,313	The Plasmodial Surface Anion Channel As A Target For Antimalarial Therapy
	6/11/2019	E-051-2002	10,314,908	Method of Controlling Inflammation
	12/22/2020	E-145-2011	10,869,865	The Plasmodial Surface Anion Channel As A Target For Antimalarial Therapy
	1/5/2021	E-202-2008	10,881,669	Plasmodial Surface Anion Channel Antagonists As Lead Molecules For Antimalarial Drug Development
NIAMS	3/18/2014	E-011-2005	8,673,333	Cross-linked Polymer Matrices, And Methods Of Making And Using Same
NIBIB	2/27/2018	E-167-2014	9,903,868	Gold Nanoparticle (AuNP)-based Colorimetric Assay For Ultrasensitive Detection Of Biomarkers
	5/22/2018	E-314-2013	9,974,868	Non-spherical Iron Oxide Nanoparticles As High-Performance T2 Contrast Agents For Magnetic Resonance Imaging
	4/16/2019	E-099-2015	10,258,701	Labeled Evans Blue Dye Derivative For In Vivo Serum Albumin Labeling
	5/12/2020	E-079-2011	10,646,591	Fast Acting Molecular Beacon For Imaging Protease Activity And Uses Thereof

IC	Issue Date	Reference No.	Patent No.	Technology Title
	7/14/2020	E-143-2015	10,709,790	Chemical Conjugation Of Evans Blue Derivatives: A Strategy To Develop Long Acting Therapeutics Through Albumin Binding
NICHD	10/30/2012	E-057-2008	8,299,050	Use Of The Selective Progesterone Receptor Modulator CDB-2914 For Treating Uterine Leiomyomata And Stopping Bleeding In Patients Afflicted With Uterine Leiomyomata
	10/15/2013	E-206-2007	8,557,844	Treatment Of Smith-Lemli-Opitz Syndrome (SLOS)
	5/13/2014	E-057-2008	8,722,653	Use Of The Selective Progesterone Receptor Modulator CDB-2914 For Treating Uterine Leiomyomata And Stopping Bleeding In Patients Afflicted With Uterine Leiomyomata
	11/18/2014	E-247-2009	8,889,101	Dendrimer Based Nanodevices For Therapeutic And Imaging Purposes
	2/3/2015	E-124-2008	8,946,243	Anti-HIV Activity Of Newly-synthesized Monophosphorylated Acyclovir-based Compounds
	11/10/2015	E-057-2008	9,180,133	Use Of The Selective Progesterone Receptor Modulator CDB-2914 For Treating Uterine Leiomyomata And Stopping Bleeding In Patients Afflicted With Uterine Leiomyomata
	8/30/2016	E-206-2007	9,428,541	Treatment Of Smith-Lemli-Opitz Syndrome (SLOS)
	12/27/2016	E-042-2013	9,526,794	Injectable Dendrimer Hydrogel Nanoparticles
	6/20/2017	E-057-2008	9,682,088	Use Of The Selective Progesterone Receptor Modulator CDB-2914 For Treating Uterine Leiomyomata And Stopping Bleeding In Patients Afflicted With Uterine Leiomyomata
	2/18/2020	E-247-2009	10,561,673	Dendrimer Based Nanodevices For Therapeutic And Imaging Purposes
NIDA	6/1/2004	E-087-2002	6,743,797	Methods For Preventing Or Treating Cardiac Arrhythmia
	4/20/2010	E-087-2002	7,700,600	Methods For Preventing Or Treating Cardiac Arrhythmia
	6/1/2010	E-269-2006	7,728,001	Opioid Receptor Ligands And Methods For Their Preparation
	5/28/2013	E-087-2002	8,450,325	Methods For Preventing Or Treating Cardiac Arrhythmia
	6/10/2014	E-128-2006	8,748,608	4-Phenylpiperazine Derivatives With Functionalized Linkers As Dopamine D3 Receptor Selective Ligands With Drug Abuse Therapeutic Potential
	4/11/2017	E-221-2010	9,617,229	Phenylmorpholines And Analogues Thereof
	1/9/2018	E-073-2013	9,862,679	Phenyl-substituted Thioacetamide And Sulfinylacetamide Modafinil Derivatives As Monamine Transport Inhibitors: Preparation And Use In The Treatment Of CNS Disorders

IC	Issue Date	Reference No.	Patent No.	Technology Title
	3/17/2020	E-073-2013	10,590,074	Phenyl-substituted Thioacetamide And Sulfinylacetamide Modafinil Derivatives As Monamine Transport Inhibitors: Preparation And Use In The Treatment Of CNS Disorders
	2/9/2021	E-073-2013	10,913,711	Phenyl-substituted Thioacetamide And Sulfinylacetamide Modafinil Derivatives As Monamine Transport Inhibitors: Preparation And Use In The Treatment Of CNS Disorders
NIDCR	11/1/2011	E-001-2008	8,048,641	Micropatterning Of Extracellular Matrix Proteins Using Microphoto-ablation Of Poly(vinyl Alcohol) (PVA) Monolayers
	12/30/2014	E-038-2013	8,921,340	SYNTHETIC TRITERPENOID AND TRICYCLIC-BIS-ENONES FOR USE IN STIMULATING BONE AND CARTILAGE GROWTH
	3/8/2016	E-257-2012	9,278,090	MTOR Inhibition Prevents Epithelial Stem Cell Senescence And Protects From Radiation-induced Mucositis
NIDDK	4/3/2007	E-171-2003	7,199,127	Adenosine Derivatives As A3 Receptor Agonists
	5/5/2009	E-329-2000	7,528,274	Novel Acythiol Compositions And Methods of Making and Using Them
	1/5/2010	E-146-2001	7,642,280	Novel Bromotyrosine-derived Alkaloids That Inhibit The Enzyme Mycothiol Amidase
	2/22/2011	E-264-2003	7,893,094	Pyridinium Compounds To Treat Cystic Fibrosis And Other IL-8 Dependent Disorders
	12/13/2011	E-329-2000	8,076,372	Novel Acythiol Compositions And Methods of Making and Using Them
	4/16/2013	E-091-2006	8,420,664	Allosteric Enhancers Of The A3 Adenosine Receptor
	5/27/2014	E-140-2008	8,735,407	Design Of (N)-Methanocarba Adenosine 5'Uronamides As Species-Independent A3 Receptor-Selective Agonists
	6/3/2014	E-284-2008	8,741,259	Low Molecular Weight Thyroid Stimulating Hormone Receptor Agonists
	9/2/2014	E-102-2011	8,822,434	(N)-Methanocarba Phosphonate Analogues Of 5'-AMP As Cardioprotective Agents
	12/23/2014	E-140-2008	8,916,570	Structure-Based Design Of A3 Adenosine Receptor-Selective 2-Arylethynyl (N)-Methanocarba Nucleosides
	4/28/2015	E-109-2006	9,018,371	Novel, Potent And Selective A3 Adenosine Receptor Antagonists
	10/13/2015	E-308-2006	9,156,778	Cross-Coupled Peptide Nucleic Acids For Detection Of Nucleic Acids Of Pathogens
	11/10/2015	E-285-2008	9,181,253	Truncated (N)-Methanocarba Nucleosides As A1 Adenosine Receptor Agonists And Partial Agonists: Receptor Docking And Potent Anticonvulsant Activity

IC	Issue Date	Reference No.	Patent No.	Technology Title
	11/17/2015	E-284-2008	9,187,457	Low Molecular Weight Thyroid Stimulating Hormone Receptor Agonists
	3/29/2016	E-284-2008	9,296,729	Low Molecular Weight Thyroid Stimulating Hormone Receptor Agonists
	4/5/2016	E-102-2011	9,303,053	(N)-Methanocarba Phosphonate Analogues Of 5'-AMP As Cardioprotective Agents
	5/3/2016	E-091-2006	9,326,978	Allosteric Enhancers Of The A3 Adenosine Receptor
	10/4/2016	E-284-2008	9,458,141	Low Molecular Weight Thyroid Stimulating Hormone Receptor Agonists
	12/27/2016	E-102-2011	9,526,739	(N)-Methanocarba Phosphonate Analogues Of 5'-AMP As Cardioprotective Agents
	4/11/2017	E-234-2011	9,616,139	Conjugating Amines
	5/8/2018	E-742-2013	9,963,450	Phenotypic Screening For Treating Chronic Neuropathic Pain: Focus On 2-Arylethynyl Substitution Of A3 Adenosine Receptor Agonists
	7/10/2018	E-121-2019	10,016,432	METHANOCARBA DERIVATIVES OF PSEUDORIBOSE THAT INHIBIT ADENOSINE KINASE
	2/12/2019	E-161-2014	10,202,367	Development Of A Novel Class Of Compounds In Treatment Of Hepatitis C
	10/29/2019	E-260-2012	10,457,978	Cyclopentane-Peptide Nucleic Acids For Qualitative And Quantitative Detection Of Nucleic Acids
	3/3/2020	E-742-2013	10,577,368	Phenotypic Screening For Treating Chronic Neuropathic Pain: Focus On 2-Arylethynyl Substitution Of A3 Adenosine Receptor Agonists
	6/16/2020	E-213-2015	10,683,277	Structure-Based Design Of Alkyne And Triazole Derivatives As P2Y14 Receptor Antagonists
NIEHS	1/4/2005	E-266-2007	6,838,580	New Opioid Derivative
NIMH	7/22/2014	E-174-2006	8,785,500	Intranasal Administration Of Ketamine To Treat Depression
	10/14/2014	E-175-2004	8,859,585	Scopolamine For The Treatment Of Depression And Anxiety
	1/10/2017	E-174-2006	9,539,220	Intranasal Administration Of Ketamine To Treat Depression
	3/14/2017	E-174-2006	9,592,207	Intranasal Administration Of Ketamine To Treat Depression
	7/18/2017	E-175-2004	9,707,220	Scopolamine For The Treatment Of Depression And Anxiety
NINDS	3/27/2007	E-167-2004	7,194,978	Inducing Sterility In Fish By Disrupting The Development Of The GNRH System
	4/12/2016	E-025-2012	9,308,163	Diffusion Through Skull As Route Of Delivery For Treatments Of Brain Injury And Disease
	1/24/2017	E-030-2013	9,550,742	Selective Human D2 Dopamine Receptor Antagonists As Potential Antipsychotic Agents

IC	Issue Date	Reference No.	Patent No.	Technology Title
	5/22/2018	E-025-2012	9,974,801	Diffusion Through Skull As Route Of Delivery For Treatments Of Brain Injury And Disease